Neutralizing ACBP/DBI in mouse osteoarthritis: the target was an endogenous protein

A mouse treatment study targeted ACBP/DBI and should not be mistaken for a study of prescribed diazepam.

The actual target

Acyl-CoA-binding protein is encoded by the gene also called diazepam-binding inhibitor. The paper found increased circulating ACBP/DBI in severe human osteoarthritis and studied gene deletion or antibody neutralization in a surgically induced mouse model. These interventions reduced selected inflammatory, structural, and functional disease measures.

The study did not administer diazepam as an osteoarthritis treatment or establish that the medicine caused the protein changes.

Human association and mouse intervention differ

Human tissue and plasma observations support relevance, while the interventional outcomes came from an animal model. They do not establish an effective antibody treatment in patients. The protein’s historical name is especially easy to confuse with medication exposure.

For interpretation, specify the endogenous target and the actual intervention. The paper supports investigation of ACBP/DBI biology, not an inference about benzodiazepine consumption from a protein measurement.

Source paper

Original analysis of the supplied journal article, identified as PMC12326017.

Related research

• Diazepam-Binding Inhibitor Protein Emerged as a Subgroup Candidate in Autism Cell-Line Research
• Miscarriage Procedure Trial Found Better Pain Scores With Local Block Than Diazepam–Pentazocine Sedation